A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

This is a randomized, double-blind, placebo controlled, multi-center study to evaluate the safety, tolerability and potential effects of dietary supplement Violet™ Iodine on breast health in women with cyclic breast discomfort and tenderness to eliminate the evaluation of effectiveness.

Study Overview

• Status: Completed
• Conditions: Fibrocystic Breast Condition (FBC)
• Intervention / Treatment: Other: Placebo; Dietary supplement: Violet™ Molecular Iodine (I2)

• Study Type: Interventional
• Enrollment (Actual): 31
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • London, Ontario, Canada, N6A5R8
      • KGK Synergize
• United States
  • Florida
    • Orlando, Florida, United States, 32806
      • KGK Synergize

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Healthy premenopausal females ≥ 18 years of age
• BMI 20.0 - 29.9 kg/m2 (± 1 kg/m2)
• Females of childbearing potential must agree to use a reliable and consistent method of birth control in the Investigator's opinion, excluding depot contraceptives and Explanon, and have a negative urine pregnancy test result. Hormonal contraceptives such as oral contraceptives, birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing) are all acceptable as long as the subject is on a stable dose and agrees not to change during the study period
• No apparent health conditions that in the investigator's opinion would interfere with study participation, compliance or interpretation of endpoints or would not be in the best interest of the subject
• Moderate to severe cyclic breast discomfort of at least 4 days per month (discomfort ≥4 on a 0-10 scale)
• No known medical or psychological condition that in the investigator's opinion could interfere with study participation
• Agrees to comply with all study related procedures and visits including access to a smartphone (Android or iOS) and ability to enter daily diary information via a smart phone app
• Capable of reading and understanding study related materials (in English or French) and has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

• Women who are pregnant, breast feeding, or planning to become pregnant during the course of the trial
• Perimenopausal or irregular menstrual cycles
• Women who have had an oophorectomy
• Known thyroid condition or currently taking any thyroid medications
• Prior bariatric surgery or other interventions or medications that might affect gastric pH
• Use of iodine supplementation, Tamoxifen, Lupron, or Danazol, in the last 6 months
• Clinically significant abnormal laboratory results at Screening
• Breast implant surgeries that have not fully healed or have ongoing problems associated with the implant (i.e. seroma, infection etc.)
• Planned elective surgeries to occur during participation in the study
• Known allergy or sensitivity to study product ingredients (e.g. Iodine)
• History of alcohol or drug abuse within the past year
• Use of medicinal marijuana within the past year
• Participation in a clinical research trial within 30 days prior to randomization or plans to participate in any other study during the next 11 months
• Individuals who are cognitively impaired and/or who are unable to give informed consent
• Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures, may confound interpretation of study outcome measures (such as another condition) or which may pose significant risk to the subject

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Violet™ Iodine; 3mg molecular iodine (I2) daily	Dietary supplement: Violet™ Molecular Iodine (I2)
PLACEBO_COMPARATOR: Placebo; 3mg placebo daily	Other: Placebo
ACTIVE_COMPARATOR: Cross-over; Subjects on placebo will be offered 3 months of active post-treatment	Dietary supplement: Violet™ Molecular Iodine (I2)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in self assessed cyclic breast discomfort	After 6 months of active treatment with molecular iodine (I2) compared to placebo

Collaborators and Investigators

• Sponsor: BioPharmX, Inc.

Study record dates

Study Major Dates

• Study Start: February 1, 2016
• Primary Completion (ACTUAL): January 31, 2018
• Study Completion (ACTUAL): January 31, 2018

Study Registration Dates

• First Submitted: February 3, 2016
• First Submitted That Met QC Criteria: February 5, 2016
• First Posted (ESTIMATE): February 8, 2016

Study Record Updates

• Last Update Posted (ACTUAL): July 10, 2018
• Last Update Submitted That Met QC Criteria: July 9, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Keywords: cyclic mastalgia; FBC; breast discomfort
• Additional Relevant MeSH Terms: Skin Diseases; Breast Diseases; Fibrocystic Breast Disease; Physiological Effects of Drugs; Anti-Infective Agents, Local; Anti-Infective Agents; Trace Elements; Micronutrients; Iodine; Cadexomer iodine
• Other Study ID Numbers: 16VBHB